ReviewNon-invasive strategies for targeting the posterior segment of eye
Graphical abstract
Introduction
The management and treatment of various disorders of the anterior and posterior segment of the human eye is a challenging task. The disorders associated with the posterior segment of human eye may lead to visual impairment, which ultimately may result in blindness (Araújo et al., 2011, Thrimawithana et al., 2011). The eye is an organ of sight and each eyeball of the human eye lies in a quadrilateral pyramid shaped bony cavity located on either side of the root of nose called orbit. The human eye measures antero-posteriorly about 24 mm in adults (Nema and Nema, 2011). Each eyeball can be classified into anterior and posterior segments. The portion behind the lens of the eye is called the posterior segment. The anterior segment of the eye contains cornea, pupil, iris, ciliary body, conjunctiva, anterior chamber, lens and aqueous humor whereas the posterior segment of the eye contains vitreous humor, sclera, choroid and retina (Aparicio-Blanco and Torres-Su&rez, 2015; Janagam et al., 2017). The disorders of the anterior segment of the human eye includes corneal infections and disorders like pterygium, Fuch’s dystrophy, dry eyes, auto immune disorders e.g., ocular cicatricle pemphigoid and cataracts (Ray, 2009). Similarly the disorders of the posterior segment includes glaucoma, cytomegalovirus retinitis (CMV), age related macular degeneration (Rokhade et al., 2007), diabetic retinopathy (DR), retinitis pigmentosa (RP), proliferative vitreoretinopathy (PVR), and inflammations of uvea (Azadi et al., 2007, Bastawrous, 2017, Thrimawithana et al., 2011, Yasin et al., 2014). A variety of drug delivery systems have been devised to overcome the limitations of conventional drug delivery systems regarding management of eye diseases (Del Amo and Urtti, 2008a). This review aims to discuss about various non-invasive strategies for the effective targeting of therapeutic agents at the posterior segments of the eye. The eye is a very sensitive organ and treatment of anterior and posterior segments of eye require surgical procedures and various invasive and painful techniques (Yasukawa et al., 2004). In addition to these issues the surgical procedures may cause retinal detachment, endopthalmitis and even. Although variety of advancements have been done in order to achieve effective ophthalmic treatments, but the reported literature describes about the invasive techniques, which require special medical assistance (Bourges et al., 2006). This review is based on advanced, safe and effective non-invasive treatment and drug delivery strategies that may effectively target the posterior segments of eye. This review focuses on the spreading of awareness to the general public and health care providers about the safe, effective, convenient and economic ophthalmic treatment techniques. The non-invasive strategies of drug targeting are presented and discussed in detailed in the next sections.
Section snippets
Challenges in ocular drug delivery approaches
Efficient drug delivery for the treatment of various anterior and posterior eye diseases has been a challenge due to the critical micro environment that exists in the eye and blood ocular barriers (blood aqueous and blood retinal barrier). The drug delivery targets in eye can be divided into four different parts, the pre-corneal area (conjunctiva, eyelids), cornea, anterior segment of eye (iris, cilliary body, and lens) and posterior segment of eye (retina, vitreous cavity) (Mandal et al., 2017
Non-invasive strategies for drug delivery to the posterior segment of eye
The development of drug delivery systems to both the anterior and posterior segments of the eye is one of the most important issue for recent pharmaceutical technology (Robinson et al., 2016). The delivery of the drug to the posterior segment of the eye is very difficult, because various static and dynamic barriers restrict or completely hamper the therapeutic agent to reach to the posterior segment. One way to deliver drugs to the posterior segment is the frequent intraocular injection, but
In vitro/In vivo models to study retinal nerve damage
In vivo models to study drug targeting to eye include mouse, rat, rabbit, monkey and human beings. Drug or drug delivery system is applied topically to be absorbed from corneal epithelium and reach the posterior segment of the eye (Chastain et al., 2016). Topical application of high molecular weight and hydrophilic drugs results in low bioavailability due to poor absorption. The unabsorbed portion of drug may be absorbed through intraocular routes, such as conjunctiva or may enter the systemic
Critical review
Conventional dosage forms had been used for the management and treatment of various ocular disorders. The conventional dosage forms employed for the management of eye diseases include solutions, suspensions, emulsions, ointments, lotions, ocular inserts, contact lenses, paper strips, collagen shields and ophthalmic rods. The problem associated with conventional dosage forms is that these are unable to cross static and dynamic barriers of the eye to treat posterior segment eye diseases so the
Conclusions
Ocular drug delivery is an important area of research. This review summarizes several research approaches to enhance the targeting of drugs to posterior segment of the eye by novel minimally invasive and non-invasive strategies. In recent years, intravitreal injections, trans-scleral and intravitreal implants achieved the broader scientific attention of researchers and clinical practitioners. The intravitreal injections have been proved to achieve the therapeutic drug concentrations in the
Declaration of interest
The authors declare no competing financial interest.
Acknowledgements
Nayab Tahir acknowledge the International Research Support Initiative Program (IRSIP) of Higher Education Commission of Pakistan for the travel grant for University of Helsinki, Finland. H.A. Santos acknowledges financial support from the Academy of Finland (decision no 304844), the University of Helsinki Research Funds, and the European Research Council under the European Union’s Seventh Framework Programme (FP/2007-2013, Grant no. 310892).
References (284)
- et al.
Lincomycin hydrochloride loaded albumin microspheres for controlled drug release, produced by Supercritical Assisted Atomization
J. Supercrit. Fluids
(2017) - et al.
Diclofenac-loaded biopolymeric nanosuspensions for ophthalmic application
Nanomed.: Nanotechnol. Biol. Med.
(2009) - et al.
In situ gelling systems based on Pluronic F127/Pluronic F68 formulations for ocular drug delivery
Int. J. Pharm.
(2016) - et al.
Polymer–lipid based mucoadhesive microspheres prepared by spray-congealing for the vaginal delivery of econazole nitrate
Eur. J. Pharm. Sci.
(2009) - et al.
In situ gelling systems: a strategy to improve the bioavailability of ophthalmic pharmaceutical formulations
Drug Discov. Today
(2014) - et al.
Ocular tolerability and efficacy of a cationic emulsion in patients with mild to moderate dry eye disease–A randomised comparative study
J. Francais d'ophtalmologie
(2014) - et al.
Novel biodegradable polyesteramide microspheres for controlled drug delivery in Ophthalmology
J. Control. Release
(2015) - et al.
Formulation and evaluation of cefuroxim loaded submicron particles for ophthalmic delivery
Int. J. Pharm.
(2015) - et al.
Nanostructured lipid carriers for triamcinolone acetonide delivery to the posterior segment of the eye
Colloids Surf. B: Biointerfaces
(2011) - et al.
CNTF+ BDNF treatment and neuroprotective pathways in the rd1 mouse retina
Brain Res.
(2007)
Intraocular concentration and pharmacokinetics of triamcinolone acetonide after a single intravitreal injection
Ophthalmology
Intravital microscopy at the single vessel level brings new insights of vascular modification mechanisms induced by electropermeabilization
J. Control. Release
Intraocular implants for extended drug delivery: therapeutic applications
Adv. Drug Deliv. Rev.
Nanoparticles in cancer therapy and diagnosis
Adv. Drug Deliv. Rev.
Polymeric nanoparticles for optical sensing
Biotechnol. Adv.
Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin
Int. J. Pharm.
CHAPTER 7 – Recent Advances in Ophthalmic Drug Delivery A2 – Kulkarni, Vitthal S, Handbook of Non-Invasive Drug Delivery Systems
Distribution of topical ocular nepafenac and its active metabolite amfenac to the posterior segment of the eye
Exp. Eye Res.
Iontophoresis-driven penetration of nanovesicles through microneedle-induced skin microchannels for enhancing transdermal delivery of insulin
J. Control. Release
The potential use of novel chitosan-coated deformable liposomes in an ocular drug delivery system
Colloids Surf. B: Biointerfaces
Development of a predictive model for the stabilizer concentration estimation in microreservoir transdermal drug delivery systems (MTDDS) using lipophilic pressure sensitive adhesives as matrix/carrier
J. Pharm. Sci.
Sustained reduction of intraocular pressure by supraciliary delivery of brimonidine-loaded poly (lactic acid) microspheres for the treatment of glaucoma
J. Control. Release
In vivo evaluation of a biodegradable donut‐shaped minitablet for prolonged posterior segment drug delivery in the rabbit eye model
J. Pharm. Sci.
Iontophoretic transport of charged macromolecules across human sclera
Int. J. Pharm.
Sustained release micellar carrier systems for iontophoretic transport of dexamethasone across human sclera
J. Control. Release
Evaluation of dexamethasone phosphate delivered by ocular iontophoresis for treating noninfectious anterior uveitis
Ophthalmology
Current strategies for engineering drug nanoparticles
Curr. Opin. Colloid Interface Sci.
Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporin A
Int. J. Pharm.
Current and future ophthalmic drug delivery systems: a shift to the posterior segment
Drug Discov. Today
Novel inulin-based mucoadhesive micelles loaded with corticosteroids as potential transcorneal permeation enhancers
Eur. J. Pharm. Biopharm.
Applications of nanoparticles in ophthalmology
Prog. Retin. Eye Res.
Microencapsulation of essential oil of pimento [Pimenta dioica (L) Merr.] by chitosan/k-carrageenan complex coacervation method
Innov. Food Sci. Emerg. Technol.
Transdermal iontophoresis of ranitidine: an opportunity in paediatric drug therapy
Int. J. Pharm.
Novel in situ gel systems based on P123/TPGS mixed micelles and gellan gum for ophthalmic delivery of curcumin
Colloids Surf. B: Biointerfaces
Iontophoresis: a non-invasive ocular drug delivery
J. Control. Release
J. Control. Release
Charged nanoparticles delivery to the eye using hydrogel iontophoresis
J. Control. Release
Gelatin-based nanoparticles as drug and gene delivery systems: reviewing three decades of research
J. Control. Release
Trans-scleral iontophoretic delivery of low molecular weight therapeutics
J. Control. Release
Studies on thermoresponsive polymers: phase behaviour, drug delivery and biomedical applications
Asian J. Pharm. Sci.
Formulation and pharmacokinetic evaluation of an asulacrine nanocrystalline suspension for intravenous delivery
Int. J. Pharm.
Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions
Int. J. Pharm.
Iontophoresis of minoxidil sulphate loaded microparticles, a strategy for follicular drug targeting?
Colloids Surf. B: Biointerfaces
Nanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth
Int. J. Pharm.
Stimuli-reponsive polymers and their bioconjugates
Prog. Polym. Sci.
Alginate/chitosan particulate systems for sodium diclofenac release
Int. J. Pharm.
Next generation intra- and transdermal therapeutic systems: using non- and minimally-invasive technologies to increase drug delivery into and across the skin
Eur. J. Pharm. Sci.
Iontophoresis: from the lab to the bed side
Exp. Eye Res.
Assessment of the effect of cyclosporine-A 0.05% emulsion on the ocular surface and corneal sensation following cataract surgery
Cont. Lens Anterior Eye
Hydrogel nanoparticles in drug delivery
Adv. Drug Deliv. Rev.
Cited by (43)
Advanced hydrogel-based platform for ocular drug delivery
2023, Nanotechnology in OphthalmologySirolimus loaded chitosan functionalized poly (lactic-co-glycolic acid) (PLGA) nanoparticles for potential treatment of age-related macular degeneration
2021, International Journal of Biological MacromoleculesCitation Excerpt :Similar results were obtained by other authors possibly because of adsorption of subsequent chitosan layers on PLGA nanoparticles [47] or increase in viscosity of aqueous phase [48,49]. The sizes of both the nanoparticles prepared in the present work were aimed to be kept in the range of 200 nm, keeping functionalization in mind [50], commonly proposed to be retained in the periocular tissues for providing sustained retinal drug delivery via transscleral route [7,51]. Therefore, due to the size constraints of nanocarriers for ocular delivery, CH-PLGA-NP with 0.1% w/v chitosan solution coating was selected for further SIR encapsulation and characterization.
Polymeric nanotherapeutics acting at special regions of body
2021, Journal of Drug Delivery Science and TechnologyTopical drug delivery to the posterior segment of the eye: Thermodynamic considerations
2021, International Journal of Pharmaceutics